Last reviewed · How we verify
with concurrent cisplatin chemotherapy — Competitive Intelligence Brief
phase 3
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
with concurrent cisplatin chemotherapy (with concurrent cisplatin chemotherapy) — Fujian Cancer Hospital. This is a concurrent chemotherapy regimen combining an unspecified agent with cisplatin to enhance cytotoxic effects against cancer cells.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| with concurrent cisplatin chemotherapy TARGET | with concurrent cisplatin chemotherapy | Fujian Cancer Hospital | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- with concurrent cisplatin chemotherapy CI watch — RSS
- with concurrent cisplatin chemotherapy CI watch — Atom
- with concurrent cisplatin chemotherapy CI watch — JSON
- with concurrent cisplatin chemotherapy alone — RSS
Cite this brief
Drug Landscape (2026). with concurrent cisplatin chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/with-concurrent-cisplatin-chemotherapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab